Iridoids.

Iridoid glycosides such as aucubin and oleuropein oxidise readily in aqueous solution, browning the preparation and losing the intact glycoside. Ascorbate is used in liquid formulations to slow that oxidation. This is a formulation stability effect, not evidence of a biological synergy in the body. It matters most for liquid extracts and standardised syrups.

Most iridoids occur as glucosides, and the sugar must be cleaved before the aglycone can be absorbed or act. Beta-glucosidase activity from gut bacteria performs most of this in humans, which is why absorption varies with an individual's microbiota. Supplemental digestive enzyme blends do not reliably contain the relevant beta-glucosidase. The dependency on microbial conversion is the more important point than any enzyme product.

Olive oil is itself a delivery matrix for secoiridoids, particularly oleuropein aglycone and oleocanthal, which give extra virgin oil its peppery bite. Refining strips these compounds, which is why the polyphenol content separates extra virgin from refined oil. The oil serves as both source and lipid carrier for the less polar aglycone forms. This is a compositional relationship, not a supplement pairing.

Berry preparations from Lonicera caerulea and related species carry both anthocyanins and iridoid glycosides in the same extract, so the two travel together by origin rather than by design. Trials of these standardised berry blends report on the whole extract, not on the iridoid fraction alone. Attributing an outcome from a mixed berry extract specifically to its iridoids is not supported by the way those studies were run. The pairing is real in the bottle and unresolved in the mechanism.

Both iridoid glycosides and flavonoid glycosides depend on deglycosylation before absorption and both are subject to heavy phase II conjugation in the enterocyte and liver. They compete for the same UGT and SULT conjugation capacity at high doses. Whether this raises the free fraction of either in a way that matters at supplement doses has not been demonstrated in people. The overlap is worth stating, the consequence is not established.

Silymarin flavonolignans and iridoid aglycones are both substrates for glucuronidation. Loading both heavily can slow the clearance of either, since conjugation capacity is finite. This is a plausible pharmacokinetic interaction rather than a documented one at typical intakes. Read it as a caution for high-dose stacking, not a reason to avoid the combination.

Iridoid-rich oil preparations, olive-derived ones in particular, oxidise over shelf life and lose their phenolic content. Tocopherols in the same oil slow lipid peroxidation and preserve the phenolic fraction longer. This is shelf stability chemistry that shows up as a higher assayed polyphenol figure at end of shelf life. It says nothing about what either does after ingestion.